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Plasmodium falciparum is one of four species known to cause malaria in humans and 
is the species that is associated with the most virulent form of the disease.  Malaria causes 
nearly two million deaths each year, many of these occurring among children in under-
developed countries of the world.  One reason for this is the prevalence of drug resistant 
strains of malaria that mitigate the efficacy of existing drugs.  Hence, the identification of 
a new generation of pharmacological agents for malaria is extremely urgent.   
The recent identification of a group of novel protein kinases within the Plasmodium 
falciparum genome has provided researchers with a basis for what many hope to be new 
potential drug targets for malaria.  Identified within the Plasmodium genome and a few 
select apicomplexans, these novel proteins have been predicted to be protein kinases 
based solely on certain sequence features shared with other eukaryotic protein kinases 
(ePKs).  However, to date, no significant studies to determine the function of these novel 
kinases have been performed.  Termed FIKKs, these proteins all possess a non-conserved 
N-terminal sequence that contains a Plasmodium export element (Pexel) which may 
target the proteins for export from the parasite and a conserved C-terminal catalytic 
domain containing a FIKK sequence common to all twenty members of this family.   
We analyzed the localization of one of the FIKK proteins, FIKK11, encoded by the 
PF11_0510 locus, during intraerythrocyte differentiation of P. falciparum by Western 
blot analysis and indirect immunofluorescence assay.  Western blot analysis 
demonstrated that FIKK 11 is expressed within the parasite at all stages of its erythrocytic 
life cycle with its highest expression occurring during the schizont stage. 
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Immunofluorescence assays showed that this protein is exported from the Plasmodium 
parasite into the host erythrocyte cytosol which is consistent with studies on other 
Plasmodium proteins that also have the Pexel motif.   
To determine the enzymatic activity of FIKK11, we overexpressed the recombinant 
protein in E. coli and then purified it.  However, no protein kinase activity was detected 
using several commonly used protein kinase substrates including histone H1, myelin 
basic protein, or dephosphorylated casein.  We also did not detect any kinase activity of 
the native enzyme using pull-down assays of the Plasmodium falciparum cell extract 
against those same substrates.  In addition, kinase substrate peptide array analysis of 
FIKK11 showed no evidence of protein kinase activity either for FIKK11.  Interestingly, 
however, we were able to detect some kinase activity using the recombinant protein alone 
with no substrate.   
The lack of the glycine triad within subdomain I of these FIKK kinases as compared 
with most traditional eukaryotic protein kinases may explain why we were unable to find 
any interactions between FIKK11 and other commonly protein kinase substrates.  Of 
interest was the observation that the protein reproducibly exhibited what appeared to be 
an autophosphorylation activity when using the standard protein kinase assay.  Further 
analyses, however, showed that FIKK11 actually possesses diacylglycerol kinase activity 
utilizing 1-Stearoyl-2-arachidonoyl-sn-glycerol as a substrate.  This is the first evidence 
of diacylglycerol kinase activity in Plasmodium falciparum.  Because FIKK11 is 
exported into the host cell and is localized on the erythrocyte membrane, its enzymatic 
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CHAPTER ONE: INTRODUCTION 
 
Background 
 The genus, Plasmodium, is the causative agent of malaria, a diesease that 
threatens approximately 40% of the world’s population (Breman, 2001).  The 
majority of the cases of malaria are found in the tropical and subtropical regions 
of the world and this disease results in 300 to 500 million clinical cases per year 
with one to three million of those cases leading to death (Breman, 2001).  Of the 
known species of Plasmodium, four have been identified as being directly 
responsible for infection of the human host: P. falciparum, P. vivax, P. malariae, 
and P. ovale.  Among these four species, Plasmodium falciparum is responsible 
for the majority of the clinical cases of malaria and is, consequently, the most 
lethal. 
The word malaria comes from the Italian term mal’aria that translates into 
“bad air”.  Its name comes from the belief among ancient cultures that the fevers 
common among the disease state were caused by breathing bad air within certain 
areas that had become inundated with standing, stagnant water.  In 1716, the 
Italian physician Giovanni Maria Lancisi saw black pigmentation of brain and 
spleen samples from patients suffering from malarial symptoms.  The first 
observation of the parasite itself, however, came in 1847 when the German 
scientist Heinrich Meckel observed black-pigmented granules in the blood and 
spleen of a deceased, diseased patient.  It wasn’t until 1879 that Afanasiev 
1 
suggested that the disease state itself was actually caused by the granules.  In 
1880, Louis Alphonse Laveran identified the parasite in human erythrocytes and 
described both trophozoite and schizont stages of the parasite.  By 1897, the 
combined work of Patrick Manson and Ronald Ross confirmed that the parasite 
was transmitted to its human host via the mosquito vector. 
The first actual treatment for malaria came in 1820 with the discovery of 
quinine, an alkaloid from the bark of the Cinchona ledgeriana tree.  As the supply 
of quinine became limited during World War II, and soldiers were exposed to 
potential malaria on tropical and subtropical battlefields, there was an increase in 
research for synthetic antimalarial drugs.  This prompted the discovery 
chloroquine in 1934 (Greenwood, 1995; Schmidt and Roberts, 1989).  
Chloroquine has remained one of the most commonly prescribed treatments for 
malaria, partially because of its low production costs.  The last several decades, 
however, have seen an alarming increase in the number of chloroquine-resistant 
cases throughout the world.  The causes for this increase have been attributed to 
incorrect drug dosing, patient noncompliance with the duration of their treatment, 
poor drug quality and misdiagnosis (Bloland, 2001).  Because most other 
antimalarial drugs are chemically related to chloroquine, many show drug-
resistance to strains of malaria within a few years of release.  This rise in 
resistance to antimalarial drugs makes the search for new, novel antimalarial 
agents more critical than ever.  By having a better understanding of just how 
cellular functions within the Plasmodium parasite are regulated, this search for a 
consistent, effective treatment will have a better chance of reaching fruition. 
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Plasmodium falciparum Life Cycle 
 The life cycle of the malaria parasite is quite complex as can be seen in 
fig. 1.  The Anopheles mosquito acts as the vector for the infection of a human 
host with Plasmodium falciparum.  Infection of the human host begins when the 
mosquito delivers sporozoites into the bloodstream which then travel to the liver 
and establish an infection inside the host’s hepatocytes.  Here they undergo 
multiple rounds of multiplication called exo-erythrocytic schizogony that results 
in the formation of thousands of merozoites.  These merozoites are then freed and 
infect the host’s erythrocytes where they undergo additional schizogony resulting 
in the actual pathogenesis of the malaria parasite.  Some of the merozoites may 
arrest their cell cycle and develop into male or female gametocytes that may then 
infect the mosquito vector should a subsequent bite occur.  Once inside the 
mosquito, these gametocytes become gametes that then fuse to form a zygote.  
The zygote undergoes sporogony leading to the production of sporozoites.  These 
sporozoites accumulate in the salivary glands of the where they await infection of 
a new human host. 
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Figure 1. Life Cycle of the Plasmodium falciparum Parasite 
Image borrowed from http://www.cdc.gov/malaria/images/graphs/malaria_LifeCycle.gif
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A Novel Set of Plasmodium falciparum Kinases 
 With the increase in resistance of malaria to chloroquine and other 
chemotherapeutic agents, researchers are exploring new drug targets as potential 
agents in the fight against malaria.  An interesting trend is the examination of 
protein kinases as chemotherapeutic agents.  A well-documented example of this 
is the drug Gleevec produced by Novartis.  This protein kinase inhibitor is used as 
a treatment for various forms of cancer since protein kinases are an important 
family of proteins that regulate diverse cellular activities. 
 Sequencing of the P. falciparum genome (Gardner et al., 2002) has led to 
the identification of the complete repertoire of parasite protein kinases based on 
homology searches (Ward et al., 2004).  These searches, however, have only 
identified 65 protein kinases within the malaria genome which seems quite low 
compared to Saccharomyces cerevisiae which has a similar number of total genes 
but encodes nearly twice the number of protein kinases.  The implication is that 
malaria protein kinases may possess more complex and novel cellular functions 
when compared to other eukaryotic kinomes.  Of the Plasmodium falciparum 
protein kinases identified, the presence of a novel family of 20 putative protein 
kinases is particularly noteworthy (Schneider and Mercereau-Puijalon, 2005: 
Ward et al., 2004).  This family of kinases is termed FIKK for the presence of a 
conserved amino acid sequence motif: phenylalanine-isoleucine-lysine-lysine 
(Ward et al., 2004).  All family members contain a non-conserved N-terminal 
domain and a conserved C-terminal kinase domain (Fig. 2).  Although FIKK 
5 
orthologues have been identified in other Plasmodium species and certain 
apicomplexans (Toxoplasma gondii and Cryptosporidium parvum), only P. 
falciparum and P. reichenowi exhibit extensive gene amplification with twenty 
distinct kinases found in the former and six found in the latter. 
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Figure 2. The Plasmodium falciparum FIKK Gene Family 
The black bar shows the C-terminal kinase domain; the white bar shows the polymorphic 
region within the kinase domain; the shaded bar within the kinase domain shows the 
repeat sequence; the arrow delineates the exon borders; the asterisk shows the location of 
the Pexel motif; the shaded bar in the N-terminal region shows the signal sequence;  
represents gene that are annotated; R is ring stage; T is trophozoite stage; Sc is schizont 
stage; Mz is merozoite stage; Sp is sporozoite stage.  Figure was taken from Schneider 




FIKKs as Potential Protein Kinases 
 Sequence comparisons of conventional eukaryotic protein kinases and the 
FIKK kinases show that the FIKKs possess many the conserved residues believed 
to be important for catalytic activity with the exception of the glycine triad in 
subdomain I.  Although this sequence (GxGxxG) helps to anchor ATP or GTP in 
the catalytic cleft, the phosphotransfer ability of a kinase is not entirely dependent 
on it.  A third of human protein kinases do not contain the third glycine residue of 
the triad and the first residue is absent in about 11% of the kinases (Kostich et al., 
2002).  S. pombe MIK1 tyrosine kinase that phosphorylates p34cdc2 lacks all 
three residues of the triad (Lee et al., 1994).  P. falciparum PfPK7 kinase contains 
only the second glycine residue of the triad (Dorin et al., 2005).  Though 
catalytically inactive proteins that maintain a kinase fold are not uncommon, these 
“pseudokinases” lack selective pressure to maintain residues directly involved in 
catalysis and possess amino acid substitutions in one or more of the conserved 
catalytic residues analogous to Lys72, Asp166, or Asp184 (mammalian PKA 
numbering).   
 The invariant lysine in subdomain II that is involved in the orientation of 
α and β phosphate groups of ATP appears in the FIKK signature motif of this 
novel family of kinases.  Presence of motifs close to HRDLKPxN (HLDxxPxN) 
and APE (PPE) in subdomains VIB and VIII, respectively, suggests that FIKK 
family members may function as kinases.  The aspartic acid in the HRDLKPxN 
consensus sequence acts as a general base during catalysis to facilitate phosphate 
8 
transfer.  The aspartic acid of the conserved DFG motif (Dxx in FIKKs) 
coordinates the divalent cation that bridges with the β- and γ-phosphates of the 
purine nucleotide.  The invariant arginine residue in subdomain XI that stabilizes 
the large carboxy-terminal lobe is present in FIKKs.  Because each of these 
residues is absolutely conserved among all members of the FIKK family (Fig. 3), 
it is expected that they are likely to function as protein kinases.  The FIKK family 
exhibits 38-64% identity among the paralogs within the presumed catalytic 
domain (Schneider and Mercereau-Puijalon, 2005). 
 In spite of significant conservation of residues that are important for 
catalytic activity, the absence of the defined glycine triad calls into question their 
roles as authentic protein kinases.  Therefore it is important to confirm that these 




Figure 3. Sequence Alignment of Members of the FIKK Kinase Family with PfPK5 
The Sequence alignment was done by CLUSTALW algorithm. Conserved residues in 
eukaryotic protein kinases are indicated by a red asterisk. 
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 The N-terminal domain is not conserved among the paralogs and this 
region contains a stretch of hydrophobic residues corresponding to a predicted 
trans-membrane or signal sequence domain (Schneider and Mercereau-Puijalon, 
2005).  A recently described host-targeting signal motif, RxSRILAExxx (Hiller et 
al., 2004) is present in six of the FIKK paralogs while the Plasmodium export 
element RxLx(D, E, Q) (Marti et al., 2004) can be detected in all FIKK paralogs 
downstream of the signal sequence.  Because HT/Pexel motifs have been shown 
to mediate export of proteins beyond the parasitophorous vacuole into the 
erythrocyte cytoplasm (Hiller et al., 2004; Marti et al., 2004), it is expected that 
the FIKK kinases are also trafficked to the erythrocyte. 
 
Goal of the Work Within this Thesis 
 The distant relationship between the FIKK kinases and the more typical 
eukaryotic protein kinases generates optimism that it may be possible to engineer 
selective inhibitors targeting this novel family of kinases.  However, clear 
physiological and/or cell biological data are needed to implicate FIKK kinases as 
an attractive target for drug therapy.  Therefore, we decided to characterize 
FIKK11, a member of the FIKK family.  The goal was two-fold: first, to 
determine whether selected members of the FIKK kinase family are indeed 
expressed in vivo within the Plasmodium falciparum parasite and whether the 
proteins are exported into the host erythrocyte as is implicated by the presence of 
an HT/Pexel motif within these proteins.  Secondly, to identify the potential 
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function of selected members of the FIKK kinase family by assessing whether 
they are truly protein kinases as has been speculated.  
12 
CHAPTER TWO: METHODOLOGY 
 
Cell Culture 
Plasmodium falciparum strain 3D7 was maintained n 100mm tissue 
culture dishes using human A+ red blood cells.  The culture was incubated at 
37oC with a 5% carbon dioxide/95% air mixture.  The culture medium used was 
RP10S consisting of RPMI-1640 (MOD.) supplemented with 25mM HEPES, 
0.2% dextrose, 0.15% hypoxanthine, 25µg/ml gentamycin, and 10% human 
serum or 0.5% Albumax.  Collection of the culture for parasite isolation involves 
resuspending the cells and transferring them to a 50ml conical tube.  Release of 
the parasite from the red blood cell was achieved by treating the suspension with 
0.1% saponin followed by incubating the mixture at room temperature for five 
minutes.  Afterwards, the mixture was centrifuged at 4000rpm for seven minutes 
at 4oC to separate the parasites from the red blood cell lysate.  The supernatant 
was then removed and the pellet was resuspended in 1X PBS.  The pellet was 
washed once with PBS and was subsequently stored at -80oC until needed.  In 
order to perform stage-specific analyses on the parasite, the cell culture was 
synchronized by treatment with 5% D-sorbitol for 15 minutes at 37oC.  The D-
sorbitol treatment preferentially selects in the parasites in the ring stage (Lambros 
and Vanderberg, 1979).  The D-sorbitol was thoroughly removed from the culture 
using several washes with RPMI-1640 and the culture was resuspended in RP10S 
media as described above and plated again onto tissue culture plates.  The culture 
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was then incubated as above until the desired stage was reached and then 
harvested as above at either six or eight hour intervals to assure that ring, 
trophozoite, and schizont stages were equally represented. 
 
Plasmodium RNA Extraction 
The asynchronous Plasmodium falciparum 3D7 culture was harvested as 
previously mentioned.  After the final PBS wash, the pellet was treated with 3ml 
RNAgents Denaturing Solution (Promega) and stored at -80oC until needed.  The 
pellet was later thawed on ice and 600µl 2M sodium acetate (pH 4) was added.  
This mixture was then treated with 6ml Phenol:Chlorophorm:Isoamyl Alcohol 
and incubated on ice for fifteen minutes.  The entire mixture was then transferred 
to a DEPC-treated centrifuge tube and centrifuged at 10000g for twenty minutes 
at 4oC.  The upper, aqueous phase was transferred to a clean DEPC-treated tube 
and an equal volume of isopropanol was added and allowed to incubate at -20oC 
overnight.  The mixture was centrifuged as above and the supernatant removed 
from the RNA pellet.  2.5ml Denaturing Solution was added and the pellet was 
resuspended.  Next, 2.5ml isopropanol was added and incubated at -20oC 
overnight.  The mixture was centrifuged again as above and the supernatant was 
removed.  The pellet was then washed with 1ml ice-cold 75% ethanol and 
centrifuged as above.  The supernatant was discarded and the pellet was air-dried 
one hour.  The RNA pellet was resuspended in 100µl nuclease-free water and 
transferred to RNase-free, screw-capped microcentrifuge tubes and stored at -
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80oC until needed.  The purity and integrity of the RNA sample was verified by 
running on a 1% formaldehyde denaturing gel for three hours at 75V using 1X 
MOPS buffer before it was accepted for use in RT-PCR. 
 
cDNA Synthesis by Reverse Transcription 
 RNA obtained from the asynchronous Plasmodium falciparum 3D7 
isolates as outlined above was used to synthesize cDNA for cloning.  PlasmoDB 
was searched for valid sequences for PF11_0510 (FIKK 11) and PF10_0160 
(FIKK 10.1), two putative Plasmodium falciparum protein kinases belonging to 
the FIKK kinase family.  Based on these sequences, full length and fragment 
genes containing only the C-terminal kinase domain were then analyzed and the 
appropriate primers designed to obtain the desired sequence.  Invitrogen 
synthesized the primers for cloning the open reading frames into the pET43.1 
Ek/LIC vector.  The RT-PCR reaction was carried out using the ProStar RT-PCR 
Kit (Stratagene).  Table 1 lists the primers used cloning into pET43.1 and Table 2 








Table 1. Primer Sequences Used for Cloning into the pET43 Vector 
Primers were designed using PlasmoDB to determine the consensus sequence for priemr 




Construct Length Direction Primer Sequence Tm
Forward GAGGAGAAGCCCGGTTTACATTTTAGAAAACCACCA 50 
FIKK10.1 1.227 kb 
Reverse GACGACGACAAGATGTGGAATTTAGGTAAAAAATC 50 
Forward GACGACGACAAGATGTGGATAGAGGGTTATAAAT 50 
FIKK11 1.218 kb 






























Table 2. PCR Conditions for Amplification of FIKK10.1 and FIKK11 
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 After RT-PCR, 5µl of the PCR sample was run on a 0.8% agarose gel to 
verify the amplification.  The PCR products were purified using the QIAquick 
Purification Kit (Qiagen) and the purified samples were run again on a 0.8% 
agarose gel to verify the recovery of the product and to determine the 
concentration of the samples.  Approximately 0.2pmol of purified PCR product 
was then treated with T4 DNA Polymerase mix consisting of T4 DNA 
Polymerase, 25mM dATP, 100mM DTT, and 10X T4 DNA Polymerase Buffer 
for thirty minutes at room temperature.  The product was cloned into the pET43.1 
Ek/LIC vector utilizing the LIC sequence and then transformed into NovaBlue 
supercompetent Escherichia coli cells by heat-shock treatment as per the 
manufacturer’s protocol (Novagen). SOC media was added to the heat-shocked 
cells and the mixture incubated at 37oC for ninety minutes with agitation before 
being plated onto LB agar plates containing Kanamycin (50µg/ml).  The plates 
were incubated overnight at 37oC.  The following day, isolated colonies were 
chosen for inoculation into 5ml LB broth containing Kanamycin (50µg/ml) and 
incubated at 37oC overnight with agitation.  The cultures were then used to isolate 




 The isolated, digested inserts that corresponded to the correct size for the 
given gene were further verified by sequencing performed at the University of 
Florida DNA Sequencing Core facility using the T7 primer for forward sequences 
and the SP6 primer for reverse sequences.  The sequences were then analyzed and 
verified using the DNAstar SeqMan software.     
 
Protein Expression 
The isolated plasmids were transformed into BL21 Codon+ DE3 RIPL 
supercompetent Escherichia coli cells by heat-shock treatment and plated onto LB 
agar with Kanamycin (50µg/ml).  The plates were incubated overnight at 37oC 
and colonies selected the next day for inoculation into 5ml LB with Kanamycin 
(50µg/ml).  These cultures were incubated overnight at 37oC with agitation.  The 
following day, the cultures were used to inoculate 195ml LB with Kanamycin 
(50µg/ml) and incubated at 37oC until the OD600 reached 0.6.  At that time 1mM 
IPTG was added to induce expression of the desired protein and incubated at 27oC 
for another 4 hours.  Afterwards, the cultures were spun down at 6000rpm for 
twenty minutes, the supernatant removed, and the pellet resuspended in 10ml 
TALON Wash Buffer (50mM Sodium Phosphate pH 7, 300mM NaCl, and 
protease inhibitors (Roche Mini Complete EDTA-free)). 
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TALON Affinity Purification 
 The resuspended pellet in TALON wash buffer was thawed on ice and 
incubated for thirty minutes in the presence of 75µl Lysozyme to digest the cell 
walls.  The cell suspension was sonicated for seven cycles of twenty seconds (to 
release the proteins.  There was a rest of forty seconds between sonication cycles.  
The sonicated lysate was centrifuged at 13000rpm for twenty minutes and the 
clarified supernatant was added to pre-washed TALON beads (BD Bioscience).   
The column was washed using 1X Wash Buffer (50mM Sodium Phosphate, 
300mM NaCl, pH7) and non-bound proteins removed using 1X Extraction Buffer 
(50mM Sodium Phosphate, 300mM NaCl, pH8)..  The protein of interest was 
eluted from the column using 1X Elution Buffer (50mM Sodium Phosphate, 
300mM NaCl, 150mM Imidazole, pH7).  After elution, the protein sample was 
stored at -80oC until needed.      
 
Protein Kinase Assay 
To determine whether the purified proteins exhibited any protein kinase 
activity, the proteins were assayed for protein kinase activity in a reaction 
containing 0.1µCi of γ32P-ATP, 50µM “cold” ATP and the 5X kinase buffer 
mixture (250mM Tris-HCl (pH 7.4), 50mM MgCl2, 10mM DTT, 200mM β-
Glycerophosphate, and 0.5mM Sodium Orthovanadate).  Following incubation for 
5 minutes, 0.5µg of the FIKK 11 protein was added and the reaction was allowed 
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to incubate for one additional hour at 30º C.  At the end of this incubation period, 
the reaction was stopped by addition of 0.5M EDTA.  10µl of the reaction 
mixture was spotted onto Whatmann P81 filter discs and allowed to dry.  The 
unbound 32P was removed with 3 washes with 1% phosphoric acid.  The 
radioactivity present in the samples was measured using the Beckman scintillation 
counter.  The remaining reaction mixture was run on an SDS-PAGE gel and 
stained to verify that the protein of interest was present.  Additional kinase assays 
were done in which the incubation time of protein in the presence of radioactive 
ATP, buffer pH, and buffer ionic cofactors were varied. 
 
Glycerol Kinase Assay 
 To determine whether FIKK 11 had any glycerol kinase activity, the 
protein was incubated in the presence of glycerol and ATP using the oxidation of 
NADH to determine whether the glycerol was utilized by the kinase.  2.5mM 
ATP was incubated for five minutes in the presence of a reaction mixture (0.05M 
Triethanolamine-HCl (pH 7.0), 2.5mM MgCl2, 20mM KCl, 0.1mM β-
Mercaptoethanol, 0.2mM Phospho(enol)pyruvate, 0.2mM NADH, 2mM Glycerol, 
5U/ml Pyruvate Kinase, and 5U/ml Lactate Dehydrogenase).  Then 100ng of 
FIKK 11 or a commercially available E. coli glycerol kinase was added and the 
activity measured over the course of eight minutes using a Hewlett-Packard 8453 
spectrophotometer to determine the decrease in absorbance of NADH at 340nm.  
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The reaction velocity is measured in a coupled system with pyruvate kinase and 
lactate dehydrogenase as follows: 
Glycerol + ATP  α-Glycerophosphate + ADP 
ADP + PEP  ATP + Pyruvate 
Pyruvate + NADH + H+  Lactate + NAD+ 
 One unit of glycerol kinase results in the oxidation of one µmol of NADH 
per minute at 25oC and pH 8.9 and is measured using a spectrophotometer at 
340nm over the course of 5-8 minutes. 
 
Diacylglycerol Kinase Assay 
 To analyze whether FIKK 11 had any diacylglycerol kinase activity, the 
protein was incubated in the presence of radioactive 32P ATP and a commercially 
available diacylglyerol as described below and analyzed by thin layer 
chromatography and phosphoimaging to determine activity.  250 µM Cardiolipin 
and 500 µM 1-Stearoyl-2-arachindonoyl-sn-glycerol or 1,2-Dioleoyl-sn-glycerol 
was dissolved in 1mM Sodium Desoxycholate.  1µg FIKK 11 or commercially 
available E. coli diacylglycerol kinase was added to the lipid mixture along with a 
reaction mixture (40mM Bis-Tris (pH 7.5), 5mM MgCl2, 0.1mM EDTA, 1mM 
Spermine, 0.5mM DTT, and 0.02% Triton X-100) and incubated at room 
temperature for five minutes.  In addition, 30µM calcium was added in some 
reactions to see if it had any impact on kinase activity.  Then, 1mM ATP (with 
5µCi radioactive 32P ATP) was added and the reaction allowed to incubate at 
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room temperature for thirty minutes.  The reaction was stopped by adding 750µl 
chloroform/methanol (1:2) with 1% HCl.  Next, 1ml of chloroform/methanol (1:1) 
and 500µl 1M KCl with 0.2M phosphoric acid was added and the samples 
vortexed and centrifuged at 2000rpm for five minutes.  The lower phase was 
transferred to a new reaction tube and the samples dried under a nitrogen stream.  
The samples were then resuspended in 50µl chloroform/methanol (2:1) and 
applied to TLC silica plates (EMD Chemicals).  The plates were run using a 
chloroform/acetone/methanol/acetic acid/water (40:15:14:12:8) mixture.  The 
TLC Silica plate was then exposed BioMax MS film at -80oC before being 
developed.  Finally, the TLC plates were exposed to a phosphoimager screen 
before being scanned and analyzed using ImageQuant TL software. 
 
Plasmodium falciparum Cell-free Extract 
 Synchronized Plasmodium falciparum 3D7 cells were collected from 
intraerythrocytic cultures as previously described and stored at -80oC until 
needed.  The pellet was then resuspended in a Lysis Buffer (20mM Tris-HCl 
(pH8.0), 10mM EDTA, 800mM NaCl, 3% Triton X-100, 10mM NaF, and 10mM 
β-Glycerophosphate) with protease inhibitors (Roche Mini Complete EDTA-
free).  Lysis of the cells was done by sonication and the cell lysate was clarified 
by centrifugation at 14000rpm for twenty minutes at 4oC.  The supernatant was 
transferred to a clean microcentrifuge tube and the protein concentration was 
determined by Bradford analysis (Bradford, 1979) using Protein Assay Reagent 
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(BioRad) and varying concentrations of BSA (Sigma) as the protein standard 
based on the expected sample concentration. 
 
Generation of Polyclonal Antibodies 
 Initial Western blot analyses of the FIKK proteins were performed using 
purified antibodies obtained from Sigma Genosys.  The FIKK11 antibodies were 
raised against the DELKDNIHSKNIYNC peptide.  The peptides were emulsified 
with Freund’s adjuvant and injected into rabbits (Freund, 1956; Freund and 
McDermott, 1942).  The animals were subjected to six injections before obtaining 
the final bleed.  For additional Western blot and immunofluorescence analyses, 
purified chicken antibodies were obtained from Dr. Christian Doerig, a 
collaborator in Glasgow, Scotland.  The FIKK11 antibody was raised against the 
RFTKEKSDVRNSDEF peptide corresponding to the C-terminal portion of the 
protein.  The secondary rabbit-α-chicken antibody was obtained from commercial 
commercially sources (Jackson ImmunoResearch Labs). 
 
SDS-PAGE and Transfer of Proteins to Nitrocellulose  
Samples were resolved on SDS-PAGE as described by Ornstein and Davis 
(Davis, 1964 and Ornstein, 1964).  The samples were denatured by the addition of 
4X SDS-PAGE Gel Loading Buffer (250mM Tris (pH 6.8), 8% SDS, 40% 
Glycerol, and 20% β-Mercaptoethanol) to the protein samples and boiling the 
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mixture for five minutes.  The samples were resolved via a discontinuous buffer 
system consisting of a stacking gel made with Tris-HCl (pH 6.8) on top of a 
resolving gel made with Tris-HCl (pH 8.8), 10% Acrylamide, and a Tris-Glycine 
buffer (pH 8.3).   Pre-stained molecular weight marker (BioRad) was used as the 
standard and the samples were run on the gel for ninety minutes at 150V.  The gel 
was removed and the proteins were electrophoretically transferred to 
nitrocellulose membrane (Burnette, 1981 and Towbin, et al., 1979).  The transfer 
was performed for one hour at 100V. 
 
Immunoblot Analysis 
Immunoblot analysis was performed with polyclonal chicken and rabbit 
antibodies.  The nitrocellulose membrane was incubated in blocking solution (5% 
milk in TBS-T) overnight at 4oC.  The primary antibody was diluted (Table 3) 
with 5% milk in TBS-T before incubation on the membrane for two hours at room 
temperature.  Unbound antibodies were removed by three 10 minute washes with 
5% milk in TBS-T.  The membrane was then incubated in the presence of diluted 
(Table 3) secondary antibody for thirty minutes at room temperature.  The 
membrane was then washed three times in TBS-T for 5 minutes each wash.  Next, 
the membrane was incubated in the dark in the presence of SuperSignal West 
Femto Maximum Sensitivity Substrate (Pierce) and subsequently exposed to film 
(Classic Blue Sensitive, MidWest). 
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  Table 3. Antibody Dilutions for Western Blot Analysis 
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Indirect Immunofluorescence Assay 
Synchronous Plasmodium falciparum 3D7 was harvested from culture 
plates and placed into a 15ml or 50ml conical tube depending on the amount of 
culture collected.  500µl was transferred to a clean microcentrifuge tube and the 
cells washed with 1X PBS.  The cell suspension was centrifuged at 4000rpm for 
one minute at 4oC and the supernatant was removed before being fixed in a 4% 
Paraformaldehyde / 0.00075% Glutaraldehyde solution for thirty minutes.  The 
cells were then permeabilized by incubating them in 0.05% Triton X-100 for ten 
minutes followed by a ten minute incubation in 0.1mg/ml NaBH4 to remove any 
free aldehyde groups.  Next, the cells were blocked in 3% BSA for one hour at 
room temperature and incubated in the presence of primary antibody diluted 
(Table 4) in 3% BSA overnight at 4oC.  Three washes in 3% BSA removed any 
unbound primary antibody and the cells were incubated for one hour in the 
presence of secondary antibody diluted (Table 4) in 3% BSA in the dark at room 
temperature.  After a final PBS wash, 2µl of cells and 2µl of ToPro in Antifade 
Agent were pooled onto a 12mm round coverslip pre-coated with 1% 
Poly(ethyleneimine) solution.  The mixture was incubated for twenty minutes at 
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CHAPTER THREE: RESULTS 
 
Immunoblot Analysis of Stage-specific Plasmodium Extracts 
Microarray analysis data obtained from PlasmoDB suggests that FIKK11 
is mostly expressed in the schizont stage of the malaria life cycle with lower 
expression occurring in the ring and trophozoite stages.  However, no 
experimental evidence has yet been shown to support the expression of FIKK 
family members at the protein level using Plamsodium falciparum cultures.  To 
verify the expression of FIKK11 by the parasite in vivo, we examined 
synchronized Plasmodium cell-free extracts to ensure that each stage of the 
parasite life cycle was represented.  Fig. 4 shows a Gel Code Blue analysis of 
malarial proteins as compared to uninfected red blood cells.  To verify that 
FIKK11 is expressed in vivo, we performed a Western blot analysis using peptide 
antibodies raised specifically against its catalytic domain.  Our Western blot data 
confirms that the expression of FIKK11 begins to increase in the late 
trophozoite/early schizont stage and reaches a peak accumulation in the late 
schizont stage of the parasite’s life cycle (Fig. 5).  Furthermore, there isn’t any 
indication of FIKK11 protein expression within the uninfected red blood cells 
indicating a lack of cross-reactivity.  This data confirms that FIKK11 is indeed 
expressed within Plasmodium falciparum intraerythrocytic stages and supports the 
microarray data showing its preferential expression in the schizont-stage.  
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Figure 4. Gel Analysis of Uninfected Erythrocytes and Stage-Specific Malarial Extracts 
 
Stage-specific extracts were harvested from synchronized Plasmodium 
falciparum 3D7.  25ug of each sample were loaded onto 12.5% SDS-PAGE.  
The gel was then stained using Gel Code Blue to resolve the proteins.  Lane 1, 
Uninfected Red Blood Cells; MW, Molecular Weight Marker; Lane 2, Ring; 
Lane 3, early Trophozoite; Lane 4, Trophozoite; Lane 5, early Schizont; Lane 6, 




























Figure 5. FIKK11 is Expressed Within All Stages of the Malaria Lifecycle 
 
Stage-specific extracts were harvested from synchronized Plasmodium 
falciparum 3D7.  25ug of each sample were loaded onto 12% SDS-PAGE 
and the transferred to a nitrocellulose membrane.  Chicken-raised FIKK11 
antibodies were used as the primary antibody and commercially available 
anti-chicken antibody was used as the secondary.  The membrane was 
exposed to film and developed to resolve the image. Lane 1, Uninfected Red 
Blood Cells; MW, Molecular Weight Marker; Lane 2, Ring; Lane 3, early 
Trophozoite; Lane 4, Trophozoite; Lane 5, early Schizont; Lane 6, Schizont; 












Subcellular Localization of FIKK11 Using Immunofluorescence Imaging 
 Because of the presence of a double Host Targeting/Plasmodium Export 
Element (HT/Pexel) in FIKK11, we were interested to analyze whether FIKK11 
was indeed exported from the malarial parasite in vivo to a location within the 
periphery of the parasite membrane or to the host erythrocyte.  Using Plasmodium 
falciparum-infected erythrocytes, we performed an immunofluorescence assay to 
ascertain the localization of the protein.  Fig. 6 shows the Differential Interference 
Contrast (DIC) image and the immunofluorescence image of parasitized 
erythrocytes.  As can be seen from fig. 6, FIKK11 is localized in the erythrocyte 
plasma membrane, parasitophorous vacuolar membrane, and unknown distinct 
foci during the late ring/early trophozoite stages and not in the erythrocyte or 
parasite cytosol.  Our result is consistent with the fact that malarial proteins 
containing the HT/Pexel motifs are targeted for export from the parasite (Hiller et 
al., 2004; Marti et al., 2003).  It has also been demonstrated that exported parasite 
proteins often localize within intraerythrocytic structures called Maurer’s Clefts 
(Stanley et al., 1989; Hinterberg et al., 1994).  These will often appear as punctate 
dots when viewed using an indirect immunofluroescence assay (Nunes et al., 
2006).  Fig. 6 clearly shows a punctate appearance of FIKK11 suggesting a 
possible association between it and the Maurer’s Clefts.  Additionally, the 
fluorescence seen strongly suggests an association with the infected erythrocyte 
membrane and possibly the parasitophorous vacuolar membrane.  
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 To verify that that FIKK11 expression was found within all stages of the 
parasite life cycle beginning with the ring stage and increasing to Schizont stages 
of the parasitic infection as is suggested by the immunoblot analysis, the 
immunofluorescence assays were done with cells predominantly at those specific 
stages of the cell cycle.  Fig. 7 clearly demonstrates that the level of FIKK11 
expression does increase in vivo at the Schizont stage of the parasite.  This further 
verifies the known microarray data for this protein as well as verifies the Western 
blot analysis shown by our lab.  Interestingly, fig. 7 shows the localization of 
FIKK11 is restricted exclusively to the parasitophorous vacuolar membrane at the 
Schizont stage.  This suggests a stage-dependent dynamics of FIKK11 











Figure 6. FIKK11 is Localized within the Erythrocyte Membrane and Parasitophorous 
Vacuolar Membrane in the Early Trophozoite Stage of the Malaria Lifecycle 
 
Immunofluoresence was determined by fixing and permeabilizing cells prior to the 
addition of a primary antibody raised against FIKK11 and the addition of Alexa Fluor 
555 secondary antibody.  This figure represents a cell as visualized using the Axiovert 
100M confocal microscope. The upper left panel of each shows the DIC image of the cell 
only.  The lower left panel shows the immunofluorescence image of the FIKK11.  The 















Figure 7. FIKK11 is Localized within the Parasitophorous Vacuolar Membrane at the 
Schizont Stage of the Malaria Lifecycle 
 
Immunofluoresence was determined by fixing and permeabilizing cells prior to 
the addition of a primary antibody raised against FIKK11 and the addition of 
Alexa Fluor 488 secondary antibody.  This figure represents a cell as visualized 
using the Axiovert 100M confocal microscope. The upper left panel of each 
shows the DIC image of the cell only.  The lower left panel shows the 
immunofluorescence image of the FIKK11.  The larger panel represents the 




Cloning, Overexpression, and Purification of Malarial FIKK Kinases 
 Information gathered from the PlasmoDB database provided open-reading 
frame sequences for many of the FIKK proteins.  We chose FIKK10.1 and 
FIKK11 as candidates to study the catalytic properties of FIKK proteins (Fig. 8).   
To establish whether these FIKKs function as protein kinases and for subsequent 
functional analysis of these members of the FIKK kinase family, we amplified the 
kinase domains of FIKK10.1 and FIKK11 by RT-PCR using mRNA isolated from 
asynchronous 3D7 Plasmodium flaciparum parasites (fig. 9 and fig. 10).  We 
chose to amplify the kinase domains only because our initial attempts to express 
full-length proteins containing the N-terminal secretory domain resulted in mostly 
insoluble proteins.  The amplification of the kinase domains, however, should be 
sufficient to establish whether or not FIKK kinases are catalytically active.  The 
resulting amplified kinase domain sequences were verified by DNA sequencing 
and were cloned into the T7 RNA polymerase-driven pET43.1 Ek/LIC vector.  
Inserts for the open reading frames were verified after being released from the 
pET43.1 vector by digestion with XbaI and XhoI (Fig. 11 and fig. 12).  The 
increase in size of the released inserts is due to the presence of the genes encoding 
the Nus-His tag.  Cloning into this vector was accomplished by a ligation-
independent method that uses the 3’ → 5’ exonuclease activity of T4 DNA 
polymerase to generate single-stranded nucleotide overhangs in the insert which 
are complementary to a complementary overhang in the vector.  Following 
annealing of the vector and insert, the reaction mixture was transformed into E. 
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coli Novablue supercompetent cells.  This method is extremely efficient and most 
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Figure 9. PCR Amplification of FIKK10.1 Kinase Domain 
The Kinase domain of FIKK10.1 was amplified by RT-PCR.  The PCR 




















Figure 10. PCR Amplification of FIKK11 Kinase Domain 
The Kinase domains of FIKK11 were amplified by RT-PCR.  The PCR 




























Figure 11. Verification of FIKK10.1 Kinase Domain Cloning into pET43 by Restriction 
Enzyme Digestion 
 
The PCR products were then cloned into the pET43LIC vector using a 
ligation-independent cloning approach.  Expression constructs were digested 
with XbaI and XhoI to release the Nus-tagged insert and the restriction digest 


















Figure 12. Verificationof FIKK11 Kinase Domain Cloning into pET43 by Restriction 
Enzyme Digestion 
 
The PCR product was then cloned into the pET43LIC vector using a ligation-
independent cloning approach.  Expression constructs were digested with XbaI 
and XhoI to release the Nus-tagged insert and the restriction digest was 
resolved on 0.8% agarose gels. 
MW
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 Cells harboring the pET43.1-FIKK11 plasmid were induced with IPTG 
and the cultures were then examined to determine the solubility of the proteins 
from different fractions.  As was expected, SDS-PAGE analysis of induced 
soluble and insoluble fractions showed the Nus-FIKK fusion proteins to be 
present in the soluble fraction in sufficient amounts for subsequent purification 
















Figure 13. Induction of FIKK11 to Verify the Solubility of the Nus-tagged Fusion 
Construct 
 
BL21 (DE3) Codon+ E. coli cells were transformed with the FIKK11 
recombinant protein and induced with 1mM IPTG at 27oC overnight.  The 
cells were then spun down and resuspended in a lysis buffer and sonicated for 
6 cycles.  The soluble and insoluble fractions were separated and the samples 
run on SDS-PAGE gel.  The final gel was stained with Gel Code Blue.  MW, 
molecular weight marker; Lane 1, uninduced; Lane 2, soluble fraction; Lane 
3, insoluble fraction. 
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The His-tagged recombinant FIKK fusion proteins were purified using a 
TALON cobalt affinity chromatography (Clonetech) Clontech (Fig. 14).  This 
method uses Immobilized Metal Affinity Chromatography (IMAC) for separating 
proteins through the interaction of a histidine amino acid tag with an immobilized 
cobalt metal ion.  This can allow purification of proteins under native or 
denaturing conditions and allows for elution of the bound, His-tagged protein 
under relatively mild conditions.  Fractions were examined to determine which 
contained more of the recombinant FIKK proteins relative to other proteins.  
Fractions enriched in recombinant FIKK were then concentrated and further 
purified using a SuperDex 75 size exclusion chromatography for further 
purification.  Western blot analysis with His-tag antibodies confirmed the identity 
of the purified recombinant FIKK11 (Fig. 15).  The recombinant FIKK10.1 kinase 













Figure 14. TALON Purification of FIKK11 
Using a TALON cobalt affinity purification column, 500µl samples were 
collected and 20µl of each sample was run on SDS-PAGE gels.  The gel was 
subsequently stained with Gel Code Blue for visualization.  MW, molecular 
weight marker; Lanes 1-8, the eight fractions recovered during the TALON 
















Figure 15. Verification of FIKK11 Recombinant Kinase Domain Purification by 
Western-blot Analysis 
 
The recombinant protein expression was induced by 1mM IPTG at 270C 
overnight.  Purification of the recombinant protein was achieved by using a 
TALON cobalt affinty column (Clontech).  The recombinant protein was 
resolved on 8% SDS-PAGE.  Lane 1 is a stained gel of the purified protein; 
Lane 2 is a Western blot analysis of the recombinant protein using anti-His 
antibodies. 
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Characterization of Recombinant FIKK Protein Kinase Activity 
 The recombinant FIKK kinase domains of FIKK11 and FIKK10.1 were 
assayed for either autophosphorylation, histone H1, myelin basic protein, or 
dephosphorylated casein phosphorylation activity using a standard protein kinase 
assay with ATP as the phosphodonor.  The resulting reaction mixture was either 
spotted on phosphocellulose filters ans analyzed using a Beckman scintillation 
counter and/or run on SDS-PAGE gels for visualization by autoradiography.  
None of the potential substrates used in the assay showed any phosphorylation by 
the recombinant FIKK kinase domain proteins.  The recombinant FIKK10.1 
kinase domain also showed negligable autophosphorylation activity, however, the 
apparent autophosphorylation activity of the recombinant FIKK11 appeared to be 
quite robust (Fig. 16).  Interestingly, a significant mobility shift of the FIKK11 





















Figure 16. FIKK11 Recombinant Kinase Domain Shows Potential Autophosphorylation 
Activity 
 
Kinase activity of recombinant proteins were assessed in a reaction containing 
50 mM Tris HCl, pH7.5, 10 mM MgCl2, 1 mM DTT, 40 mM b 
glycerophosphate,100 µM sodium vanadate, 50 µM ATP, 1 µCi γ32P ATP, 0.5 
µg enzyme in a 25 µl vol for 60 min at 30ºC.  10 µl samples were spotted on 
P81 circles (Whatman) and 32P incorparation was quantitated following 













Figure 17. Autoradiography Analysis of FIKK11 Recombinant Kinase Domain Shows a 
Significant Mobility Shift 
 
Kinase activity of recombinant proteins were assessed in a reaction 
containing 50 mM Tris HCl, pH7.5, 10 mM MgCl2, 1 mM DTT, 40 mM b 
glycerophosphate,100 µM sodium vanadate, 50 µM ATP, 1 µCi γ32P ATP, 
0.5 µg enzyme in a 25 µl vol for 60 min at 30ºC.  20 µl reaction sample of 
FIKK11 was resolved on a 10% SDS-PAGE. The autoradiograph was 
exposed at -80ºC for 3 hours using Transcreen HE and BioMax MS film. 
Lane 1, no enzyme; Lane 2, wild type protein. 
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To determine whether FIKK11 required a specific bivalent-metal cofactor 
to function properly, the recombinant FIKK11 protein was incubated in the 
presence of protein kinase reaction mixtures containing various bivalent cations.  
This assay showed that the recombinant FIKK11 kinase has an absolute 
requirement for a free bivalent-metal cofactor, with Mg2+ being the preferred 
cation.  No significant catalytic activity was detected when Mn2+, Ca2+, or Zn2+ 
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Figure 18. FIKK11 Activity is Dependent on Mg2+
Purified recombinant enzyme was incubated in a kinase reaction mixture 
containing 10 mM of divalent cations. 
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 We examined the dependence of phosphorylation activity with increasing 
enzyme concentration as well.  Fig. 19 shows that the rate of the reaction is 
roughly proportional to the amount of FIKK11 recombinant enzyme present.  
About 6-7pmol of phosphate was incorporated per pmol of the enzyme.   
 To determine the reaction time for phosphorylation, kinase assays were 
continued for different durations of time ranging from one minute to one hour 
before stopping the reaction.  As can be seen in fig. 20, recombinant FIKK11 
activity was nearly linear with time beginning at 10min and showed no signs of 















Figure 19. FIKK11 Activity Increases with Enzyme Concentration 
 
0-10pmol of recombinant enzyme was incubated in a kinase reaction mixture 















Figure 20. FIKK11 Activity Increases with Incubation Time 
 
4pmol of recombinant enzyme was incubated at 30oC using a kinase assay 
system for 0-60 min. 
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Because kinases are often characterized by their sensitivity to specific 
diagnostic inhibitors, we tested the effect of a panel of inhibitors on the activity of 
recombinant FIKK11.  We used the following inhibitors:  (a) Ro-31-8220, a 
selective inhibitor for protein kinase C as well as MSK1, p90RSK, p70S6 kinase 
1, and GSK3 (Davies et al., 2000: Deak et al., 1998), (b) KT 5720, a potent 
inhibitor of protein kinase A, (c) genistein, an inhibitor of protein tyrosine kinases 
(Hidaka and Kobayashi, 1993), and (d) staurosporine, a broad-spectrum inhibtor 
of protein kinases.  Only genistein and Ro-31-8220 showed significant inhibiton 
(Fig. 21).  Genistein (4,5,7-trihydroxyisoflavone) gave an IC50 of about 25µM 
while Ro-31-8220 gave and IC50 of about 15µM.  Interestingly, the broad-
spectrum protein kinase inhibitor, staurosporine, which inhibits both Ser/Thr and 
Tyr kinase is totally ineffective against recombinant FIKK11 even at 50µM.  This 
suggests that, although recombinant FIKK11 is inhibited by a Tyr kinase inhibitor 
(genistein) and a PKC inhibitor (Ro-31-8220), it is refractory to staurosporine 
which is an effective inhibitor of both Tyr kinases and PKC.  This raises the 
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Figure 21. Effects of Protein Kinase Inhibitors on FIKK11 Activity 
The inhibitors were added to a standard protein kinase assay at various 
concentrations (5 nM-50 µM). Effects on protein phosphorylation were 
analyzed by binding to phosphocellulose paper circles (P81). 
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Determination of Plasmodium Protein Kinase Phosphorylation Specificity Using a 
Positional Scanning Peptide Library 
 Recently, Dr. Benjamin Turk of Yale University developed a rapid method 
to characterize eukaryotic protein kinase phsophorylation motifs using a 
combinatorial peptide library.  This method systematically evaluates the 
preference of a given kinase for every amino acid at each of nine sites 
surrounding the phosphorylation site of a a given substrate (Hutti et al., 2004).  
The method uses a library of roughly 200 distinct peptide mixtures each 
containing a central fixed phosphorylation site flanked on either side by 
degenerate positions.  For each of the nine positions surrounding the 
phsophoacceptor site, twenty-two peptide mixtures are made in which each of the 
twenty unmodified proteogenic amino acids as well as phosphothreonine and 
phosphotyrosine are fixed.  The entire collection consists of 198 peptides.  These 
peptide substrates are arrayed in a spatially addressable manner in a 384-well 
plate and treated with the kinase of interest and radiolabeled ATP.  Control 
reactions are also run in the absence of peptide to determine the background from 
kinase alone.  At the end of the incubation time, aliquots of each reaction are 
spotted simultaneously onto a streptavidin membrane using a capillary pin-based 
liquid transfer device.  The membrane is immersed in a quenching solution, 
washed extensively to remove unincorporated label, dried, and exposed to a 
phspohor screen.  This allows the amount of radiolabel incorporated into the 
peptide to be quantified, providing an indication of which peptides are the most 
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efficient substrates for a particular kinase.  This in turn indicates which amino 
acids at a particular position influence phosphorylation by that kinase.  This 
method has been used to profile over 50 serine-threonine and tyrosine kinses.  
Fig. 22 shows a diagrammatical representation of how the positional scanning 
peptide library works.  
 Because of the conflicting results observed when studying the 
recombinant FIKK11 kinase, samples were sent to Dr. Turk’s lab to be assayed 
for testing using the positional scanning peptide library.  Peptide array substrate 
analysis was not able to identify a single interacting peptide substrate for FIKK11. 
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 Y-A-Z-X-X-X-X-S/T-X-X-X-X-A-G-K-K(biotin)     Š5 set
Y-A-X-Z-X-X-X-S/T-X-X-X-X-A-G-K-K(biotin)     Š4 set
Y-A-X-X-Z-X-X-S/T-X-X-X-X-A-G-K-K(biotin)     Š3 set
Y-A-X-X-X-Z-X-S/T-X-X-X-X-A-G-K-K(biotin)     Š2 set
Y-A-X-X-X-X-Z-S/T-X-X-X-X-A-G-K-K(biotin)     Š1 set
Y-A-X-X-X-X-X-S/T-Z-X-X-X-A-G-K-K(biotin)     +1 set
Y-A-X-X-X-X-X-S/T-X-Z-X-X-A-G-K-K(biotin)     +2 set
Y-A-X-X-X-X-X-S/T-X-X-Z-X-A-G-K-K(biotin)     +3 set
Y-A-X-X-X-X-X-S/T-X-X-X-Z-A-G-K-K(biotin)     +4 set
22 peptides
per set x 9
sets = 198
peptides
Array in  microtiter  plate
Add kinase and γ-[32P]-ATP
Incubate at 30 ¼C















Figure 22. Peptide Array Method for Determining Protein Kinase Phosphorylation Motifs 
 
For each of 9 positions surrounding the phosphorylation site, 22 peptides are synthesized 
in which Z is fixed as one of the 20 unmodified proteogenic amino acids, 
phosphothreonine or phosphotyrosine. X positions are equimolar mixtures of all residues 
(excluding serine, threonine and cysteine). 
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Analysis of Protein Kinase Assay Components 
 Since no interacting substrates were identified against recombinant 
FIKK11, we began to suspect that our enzyme was phosphorylating some 
component within our reaction mixture.  To examine this possibility, reaction 
mixtures were made in which one of the selected components was eliminated and 
the protein kinase assay carried out as before in the presence of radiolabelled ATP.  
Only the reaction mix lacking MgCl2 prevented the phosphorylation previously 
seen from taking place (Fig. 23).  This is expected since we had earlier shown that 
MgCl2 is the preferred bivalent metal cation for this enzyme. 
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Figure 23. Removal of MgCl2 from the Reaction Mixture Eliminated the Activity of 
Recombinant FIKK11 
Standard reaction mixes were made including several that lacked one of the 
key components of the mixture.  The reaction was carried out as before and 
the resulting samples run on an SDS-PAGE gel and exposed to BioMax MS 
film overnight to determine the results.  Lane 1, no enzyme; Lane 2, enzyme 
and standard reaction mix, Lane 3, reaction mix lacking MgCl2; Lane 4 
reaction mix lacking DTT; Lane 5, reaction mix lacking β-glycerophosphate, 
















Glycerol had been used during purification of our protein to enhance the 
stability of the recombinant FIKK11, a common practice during the purification 
of proteins.  Therefore, we decided to investigate the contribution of glycerol on 
actual kinase activity to see if residual glycerol within the recombinant protein 
samples is phosphorylated which is giving us the impression of FIKK11 
autophosphorylation.  To this end, a sample of recombinant FIKK11 protein was 
purified without glycerol.  When assayed using the protein kinase assay system, 
the recombinant protein purified without glycerol showed no phosphorylation 
compared with the recombinant protein purified with glycerol (Fig. 24).  This 
result may could be due to the fact that the protein is no longer active since the 
stabilizing nature of the glycerol had been removed during its purification.  
However, another possibility is that glycerol may actually be the substrate for the 














Figure 24. Removal of Glycerol During Protein Purification Eliminated Recombinant 
FIKK11 Activity 
 
Standard reaction mixes were used on recombinant FIKK proteins purified either 
with or without the addition of glycerol and the reaction was carried out as before 
and the resulting samples run on an SDS-PAGE gel and exposed to BioMax MS 
film overnight to determine the results. Lane 1, no enzyme; Lane 2, enzyme 
purified with glycerol; Lane 3, enzyme purified without glycerol. 
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Characterization of Recombinant FIKK11 Glycerol Kinase Activity 
 Based on the observation that recombinant FIKK11 kinase showed no 
activity at all when purified in the absence of glycerol, it is possible that the 
enzyme is not a true protein kinase.  This is even more likely given the fact that 
FIKK11 lacks the traditional glycine triad common to most eukaryotic protein 
kinases.  To determine whether the recombinant FIKK11 kinase might have an 
activity other than that of a protein kinase, the enzyme was assayed using glycerol 
as a potential substrate.  The recombinant FIKK11 kinase, however, showed no 
significant glycerol kinase activity as compared to a commercially available 






























Figure 25. FIKK11 Exhibits no Glycerol Kinase Activity 
Glycerol kinase activity of FIKK11 was compared to a commercially available 
glycerol kinase using a coupled reaction to measure the oxidation of NADH.  
2.5mM ATP was incubated for five minutes in the presence of a reaction mixture 
(0.05M Triethanolamine-HCl (pH 7.0), 2.5mM MgCl2, 20mM KCl, 0.1mM β-
Mercaptoethanol, 0.2mM Phospho(enol)pyruvate, 0.2mM NADH, 2mM 
Glycerol, 5U/ml Pyruvate Kinase, and 5U/ml Lactate Dehydrogenase).  100ng of 
FIKK 11 or a commercially available E. coli glycerol kinase was added and the 
activity measured over the course of 8 minutes using a Hewlett-Packard 8453 
spectrophotometer to determine the decrease in absorbance of NADH at 340nm. 
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Characterization of Recombinant FIKK11 Diacylgycerol Kinase Activity 
 Since our data showed conclusively that FIKK11 was not a glycerol 
kinase, we tested the possibility whether the protein has any diacylglycerol kinase 
activity.  To determine whether the recombinant FIKK11 kinase has 
diacylglycerol activity, the enzyme was assayed using 1-Stearoyl-2-
arachindonoyl-sn-glycerol as a potential substrate.  As evident in fig. 26, film 
autoradiography analysis of the TLC plate shows that FIKK11 does exhibit 
diacylglycerol kinase activity when compared to a commercially available DGK 
and BSA and no enzyme used as negative controls.  Additionally, quantification 
by phosphoimage analysis of the radiolabelled spots shows that the recombinant 
FIKK11 kinase has significant activity as a diacylglycerol kinase against 1,2-SAG 
as a potential substrate.  However, the activity is significantly less than that seen 
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Figure 26. Recombinant FIKK11 Exhibits Diacylglycerol Kinase Activity 
DGK activity of recombinant proteins were assessed in a reaction containing 40mM 
Bis-Tris (pH 7.5), 5mM MgCl2, 0.1mM EDTA, 1mM Spermine, 0.5mM DTT, 0.02% 
Triton X-100, 1mM Sodium Desoxycholate, 250µM Cardiolipin, 500µM 1,2-SAG, 
1mM ATP (with 5µCi γ32P ATP) and 1µg enzyme for 30 minutes at room temperature.  
The reactions were spotted on TLC and then exposed at -800C for 30 minutes using 
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Figure 27. DGK Activity of Recombinant FIKK11 as Measured by Phosphoimaging 
DGK activity of recombinant proteins were assessed in a reaction containing 40mM Bis-
Tris (pH 7.5), 5mM MgCl2, 0.1mM EDTA, 1mM Spermine, 0.5mM DTT, 0.02% Triton 
X-100, 1mM Sodium Desoxycholate, 250µM Cardiolipin, 500µM 1,2-SAG, 1mM ATP 
(with 5µCi γ32P ATP) and 1µg enzyme for 30 minutes at room temperature. The percent 




CHAPTER FOUR: DISCUSSION 
 
The identification of a novel family of FIKK kinases within the 
Plasmodium flaciparum genome is a source of excitement for their potential as 
targets for malaria therapy.  However, little is actually known about the function 
of these proteins.  To this end, we decided to focus on the characterization of 
several of these kinases in order to better understand their role and potential use as 
drug targets.  Our studies focused on two objectives: (1) are these proteins 
actually expressed by the malaria parasite and are they exported from the malaria 
parasite into the erythrocyte cytoplasm or plasma membrane as is suggested by 
their HT/Pexel motif and (2) are these proteins true protein kinases as is suggested 
by sequence analysis? 
Our first goal was to determine whether these proteins were in fact 
expressed in vivo as has been suggested based on microarray studies.  
Immunoblot analysis using mono-specific, affinity-purified antibodies raised 
against FIKK11 confirms a stage-dependent expression of the protein in parasites 
with a peak expression in the schixont stage.  This results correlates well with the 
microarray analysis gathered from Plasmo DB. 
Since FIKK11 was shown to be present in vivo, we sought to determine 
the localization of the protein within the parasite or host erythrocyte.  Recent 
evidence regarding the HT/Pexel motif found in malarial proteins suggests that 
this motif is important in the export of those proteins into the erythrocyte cytosol 
(Hiller et al., 2004; Marti et al., 2003).  If the sequence seen in the FIKK11 
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protein is a true HT/Pexel motif, then the same should be true for it.  A recent 
study that examined the localization of FIKK4.1 and FIKK12 (Nunes et al., 2007) 
was able to show that those proteins were indeed exported from the parasite to a 
location associated with the erythrocytes membrane.  That same study, however, 
also showed that FIKK9.2 was not exported beyond the parasite cell membrane 
suggesting that not all of these FIKK proteins behave in the same manner.  Using 
an immunofluorescence assay, FIKK11 was clearly identified outside of the 
parasite, within the host erythrocyte which is consistent with previous 
observations for proteins containing the HT/Pexel motif.  The distribution of 
fluorescence within the infected erythrocytes strongly suggests an association 
with the infected erythrocyte membrane and the parasitophorous vacuolar 
membrane.  It should be noted that significant localization of the FIKK11 protein 
was detected on the erythrocyte membrane during the trophozoite stage of the 
parasite life cycle.  This may provide a basis for its role in antigenicty, something 
characterized with the R45 protein (FIKK4.2) (Schneider and Mercereau-
Puijalon, 2005).  Additionally, the localization of FIKK11 appears to change with 
the intra-erythrocytic maturation of the parasite and the expression of FIKK11 
also clearly increases with age of the parasite confirming our immunoblot data.  
Interestingly though, the expression of FIKK11 in the schizont stage appears to be 
confined only to the parasitophorous vacuolar membrane.  This suggests a 
dynamic expression of the protein based on the parasite developmental stages. 
Although no direct evidence exists that the FIKK proteins alone are truly 
protein kinases, we chose members of this family to create constructs for 
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recombinant fusion proteins.  It has been suggested that members of this family 
are true protein kinases (Nunes et al., 2007), however the studies performed were 
done using an in vivo pulldown followed by an in vitro kinase assay.  The 
problem with this approach is that the kinase activity detected in their studies 
could have come from a contaminating or associated kinase rather than the 
FIKK4.1 or FIKK12.  Additionally, their studies only looked at FIKK4.1 and 
FIKK12, so the assumption that all FIKK kinases are indeed protein kinases lacks 
support.  Our initial protein kinase assays were performed with purified 
recombinant protein and showed no phosphorylation of several standard protein 
kinase substrates.  However, there was significant activity using the recombinant 
FIKK protein alone suggesting that there may be autophosphorylation.  However, 
the significant mobility shift and general smearing of the protein seen in the SDS-
PAGE gel strongly suggests an alternative explanation may be responsible for this 
phenomena.  It is possible that the presence of a pronounced mobility shift might 
be due to the presence of something else co-purifying with the FIKK11. 
To further examine the potential of FIKK11 as a protein kinase, inhibition 
assays were performed on the recombinant FIKK11 protein but the results were 
equally confusing.  Our data showed that only Ro-31-8220, a protein kinase C 
inhibitor, and genistein, a protein tyrosine kinase inhibitor, had any inhibitory 
affect on the recombinant FIKK protein.  However, staurosporine, which is a 
broad-spectrum protein kinase inhibitor, had no affect on the activity of 
recombinant FIKK11.  KT 5720, an inhibitor of protein kinase A, also had no 
affect on the recombinant FIKK protein.  These discrepancies, along with the 
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smearing seen earlier, raise the possibility that FIKK11 is not a protein kinase 
after all. 
To confirm whether any protein kinase peptide substrate could be 
identified for FIKK11, we sent the recombinant FIKK11 protein to Dr. Benjamin 
Turk’s laboratory at Yale University for use in a phosphorylation assay using a 
combinatorial peptide library.  This method can quantify the amount of radiolabel 
incorporated into a peptide and can indicate which amino acids at a particular 
postion influence phosphorylation.  His lab has successfully profiled over 50 
serine-threonine and tyrosine kinases.  Unfortunately, no peptide sequences were 
identified to be substrates for FIKK11.  The data collected also ruled out the 
possibility that an autophopshorylation event may be occurring with FIKK11. 
The inability of Dr. Turk’s laboratory to identify a single interacting substrate 
from the peptide substrate arrays phosphorylated by eukaryotic protein kinases 
caused us to consider other possibilities for FIKK11.  Because of the general 
kinase activity observed, it became apparent that the phosphorylation previously 
observed was likely due to something within our protein kinase reaction mixture 
that was reacting with the recombinant protein.   
The use of glycerol in the purification of proteins is a common practice to 
increase the stability of the protein that has been extracted.  However, it might be 
possible that residual glycerol from the purification remains in the protein sample 
and the glycerol is the actual substrate for the recombinant FIKK11 protein.  To 
test this, additional recombinant FIKK11 was expressed and purified without the 
use of glycerol.  The recombinant FIKK proteins were then assayed using the 
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same protein kinase assay system as before.  Interestingly, the removal of glycerol 
from the purification procedure caused the cessation of phosphoryation that had 
been observed. 
Based on observations that recombinant FIKK11 kinase showed no 
activity at all when purified in the absence of glycerol, we began focusing on 
FIKK11 as a glycerol kinase.  This seemed likely given the fact that FIKK11 
lacks the traditional glycine triad common to most eukaryotic protein kinases.  To 
this end, the recombinant FIKK11 protein was measured for glycerol kinase 
activity.  Glycerol kinases catalyze the transfer of a phosphoryl group from Mg-
ATP to glycerol to generate glycerol 3-phosphate and Mg-ADP (Lin, 1976).  
Using a standard glycerol kinase assay which measures the oxidation of NADH 
through a coupled reaction involving pyruvate kinase and lactate dehydrogenase 
in intermediate steps, the activity of recombinant FIKK11 could be compared to a 
commercially available glycerol kinase to assess its potential as a true glycerol 
kinase.  Unfortunately, spectrophotometric analysis of the recombinant protein 
showed no glycerol kinase activity when compared to the positive control. 
 Having ruled out the possibility for FIKK11 to be a glycerol kinase, we 
examined its potential role as a diacylglycerol kinase.  Diacylglycerol kinases are 
responsible for the phosphorylation of the second messenger diacylglycerol to 
phosphatidic acid (Los et al., 2004).  This results in a recycling of 
phosphatidylinositol 4,5-bisphosphate that serves as an intermediate in protein 
kinase C-mediated signal transduction (Sakane et al., 1991; Goto and Kondo, 
1993).  This suggests that diacylglycerol kinases may serve to inhibit the activity 
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of PKC by attenuating diacylglycerol levels (Shindo et al., 2003).  The majority of 
work regarding diacylglycerol kinases, however, has been done using mammalian 
systems in which five different classes have been identified all of which possess 
two or three cystein-rich domains labeled C1A, C1B, and C1C and a conserved 
catalytic domain (Hurley et al., 1997).  Unfortunately, there is relatively little 
information available regarding the actual function of the many different 
isozymes and their conserved domains (van Blitterswijk and Houssa, 2000; van 
Blitterswijk and Houssa, 1999; Topham and Prescott, 2002).  The amount of 
variability within these classes makes finding a concrete common structure 
difficult.  Many of these contain an EF-hand motif responsible for calcium 
binding.  This EF-hand motif and the typical cystein-rich domains are not present 
in the FIKK11 kinase which may explain its preference for magnesium as a 
cofactor.  Indeed, recent studies involving plant diacylglycerol kinases have also 
shown members that prefer magnesium instead of calcium (Gomez-Merino et al., 
2004).  
Due to the fact that diacylglycerol kinases tend to be more heterogeneous 
in their composition displaying a wide array of structures, it is be possible that the 
recombinant FIKK11 is actually acting as a diacylglycerol kinase despite not 
displaying the structure seen among the more widely studied mammalian 
diacylglycerol kinases.  Using a diacylglycerol kinase assay system, the 
recombinant protein was measured against several diacylglycerol substrates and 
its activity compared to a commercially available diacyglycerol kinase.  
Interestingly, the recombinant FIKK11 showed a fairly significant amount of 
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activity with 1-stearoyl-2-arachidonoyl-sn-glycerol as a substrate when compared 
to the same activity seen using negative controls, although it was substantially 
less than the activity seen with the commercial diacylglycerol kinase.  Based on 
these results, coupled with the results from the protein kinase and glycerol kinase 
assays, led to the conclusion that the recombinant FIKK11 kinase actually 
possesses diacylglycerol kinase activity and not protein kinase activity as has 
been recently speculated.  The implications of these results are quite exciting 
considering this would provide yet another potential target for signaling between 
the host erythrocyte and the parasite and provides a new focus for future studies 
considering no work to date has been done looking at the role of diacylglycerol 
kinases within Plasmodium falciparum. 
The study of this novel group of FIKK proteins within the Plasmodium 
flaciparum genome focused on one protein in particular, FIKK11.  To 
characterize its potential function, the recombinant protein was cloned, expressed, 
and subjected to a series of kinase assays.  Although previous anaylsis has 
suggested that this family may function as protein kinases, at least the 
recombinant FIKK11 studied here appears to instead function as a diacylglycerol 
kinase.  The HT/Pexel motif of the protein does indeed appear to target the 
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